Spruce Biosciences (SPRB) Competitors $0.11 0.00 (-0.91%) As of 08/1/2025 03:36 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. LPCN, CASI, BLRX, ATNF, GELS, ATHA, CTXR, MRKR, DRRX, and MBRXShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Lipocine (LPCN), CASI Pharmaceuticals (CASI), BioLineRx (BLRX), 180 Life Sciences (ATNF), Gelteq (GELS), Athira Pharma (ATHA), Citius Pharmaceuticals (CTXR), MARKER THERAPEUTICS (MRKR), DURECT (DRRX), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors Lipocine CASI Pharmaceuticals BioLineRx 180 Life Sciences Gelteq Athira Pharma Citius Pharmaceuticals MARKER THERAPEUTICS DURECT Moleculin Biotech Lipocine (NASDAQ:LPCN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations. Do analysts recommend LPCN or SPRB? Lipocine presently has a consensus target price of $9.00, indicating a potential upside of 185.71%. Spruce Biosciences has a consensus target price of $131.25, indicating a potential upside of 120,312.84%. Given Spruce Biosciences' higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor LPCN or SPRB? In the previous week, Spruce Biosciences had 2 more articles in the media than Lipocine. MarketBeat recorded 2 mentions for Spruce Biosciences and 0 mentions for Lipocine. Lipocine's average media sentiment score of 0.00 beat Spruce Biosciences' score of -0.66 indicating that Lipocine is being referred to more favorably in the media. Company Overall Sentiment Lipocine Neutral Spruce Biosciences Negative Is LPCN or SPRB more profitable? Lipocine has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Lipocine's return on equity of -26.68% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -26.68% -24.77% Spruce Biosciences -555.23%-62.10%-47.49% Which has better valuation & earnings, LPCN or SPRB? Lipocine has higher revenue and earnings than Spruce Biosciences. Lipocine is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$11.20M1.50$10K-$1.02-3.09Spruce Biosciences$4.91M0.94-$47.92M-$1.32-0.08 Do institutionals & insiders believe in LPCN or SPRB? 9.1% of Lipocine shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 6.9% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, LPCN or SPRB? Lipocine has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. SummaryLipocine beats Spruce Biosciences on 10 of the 16 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.60M$786.63M$5.53B$9.37BDividend YieldN/A4.84%4.74%4.12%P/E Ratio-0.121.3728.8523.79Price / Sales0.9425.69440.8796.30Price / CashN/A19.5635.0757.18Price / Book0.066.688.255.54Net Income-$47.92M-$3.67M$3.25B$259.88M7 Day Performance-98.76%-5.23%-3.73%-4.67%1 Month Performance-98.01%-0.79%4.28%4.40%1 Year Performance-99.70%15.44%25.84%17.91% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.6965 of 5 stars$0.11-0.9%$131.25+120,312.8%-78.2%$4.60M$4.91M-0.1220Stock SplitGap DownLPCNLipocine2.6139 of 5 stars$3.33-3.2%$9.00+170.2%-38.0%$18.41M$11.20M-3.2710Positive NewsUpcoming EarningsCASICASI Pharmaceuticals3.9489 of 5 stars$1.62+9.5%$4.00+146.9%-81.7%$18.20M$28.54M-0.64180Gap UpBLRXBioLineRx2.0768 of 5 stars$4.16-2.1%$26.00+525.0%-86.1%$18.12M$28.94M-0.4740Gap DownATNF180 Life Sciences0.6122 of 5 stars$2.91-3.0%N/A+68.6%$18.12MN/A-0.197News CoverageAnalyst ForecastGap DownGELSGelteqN/A$1.83-4.2%N/AN/A$18.03MN/A0.00N/AATHAAthira Pharma3.2222 of 5 stars$0.41-9.9%$11.25+2,625.3%-88.6%$17.88MN/A-0.2040News CoverageUpcoming EarningsGap DownCTXRCitius Pharmaceuticals1.78 of 5 stars$1.54-7.8%$53.00+3,341.6%-94.3%$17.76MN/A0.0020Gap DownMRKRMARKER THERAPEUTICS4.164 of 5 stars$1.55-0.6%$13.17+749.5%-72.1%$17.65M$6.59M-1.1760DRRXDURECT1.0714 of 5 stars$0.55-2.6%N/A+19.9%$17.61M$2.03M-3.6880News CoverageAnalyst DowngradeMBRXMoleculin Biotech2.684 of 5 stars$0.55-2.9%$4.00+626.9%-70.7%$17.13MN/A0.0020News CoverageUpcoming EarningsShort Interest ↑Gap Down Related Companies and Tools Related Companies Lipocine Competitors CASI Pharmaceuticals Competitors BioLineRx Competitors 180 Life Sciences Competitors Gelteq Competitors Athira Pharma Competitors Citius Pharmaceuticals Competitors MARKER THERAPEUTICS Competitors DURECT Competitors Moleculin Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRB Stock Alerts